RP1
Phase 2Small molecule
RP1 is one of 113 small molecule programs targeting Skin Cancer. It is currently in Phase 2.
3
Indications
4
Total Trials
3
Active Trials
112
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 3
Imjudo
AstraZenecaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
CC 5013
Bristol-Myers SquibbPhase 3
Methylphenidate Hydrochloride
TakedaPhase 3
Systemic Chemotherapy
SSun Yat-sen University
Phase 3
Bempegaldesleukin
NNektar Therapeutics
Phase 3
Adjuvant Therapy
FFudan University
Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Intron a
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Squamous Cell Carcinoma1 trial
Skin Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RP1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RReplimune Inc.